Tags

Type your tag names separated by a space and hit enter

Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages.
Eur J Pharmacol. 2006 Feb 17; 532(1-2):162-9.EJ

Abstract

We have previously reported that NCX 2057, a new chemical entity bearing a nitric oxide (NO)-releasing moiety linked to the natural antioxidant ferulic acid, shows marked anti-inflammatory properties in a model of chronic brain inflammation. We have now studied the effects of NCX 2057 and its metabolic products, ferulic acid and NCX 2059, on inducible nitric oxide synthase (iNOS) expression and function in lipopolysaccharide/interferon-gamma (LPS/IFNgamma)-stimulated RAW 264.7 macrophages. NCX 2057 inhibited iNOS mRNA and protein expression (IC(50)=6.2+/-1.0 microM) without altering iNOS protein degradation rate. NCX 2057 also decreased the levels of LPS/IFNgamma-induced nitrite accumulation (IC(50)=4.3+/-0.7 microM) in RAW 264.7 cells. Conversely, NCX 2059, which does not possess NO-donating properties, was only weakly effective (IC(50) >100 microM) and ferulic acid was inactive. To understand further the mechanisms underlying anti-inflammatory properties we studied the effects of NCX 2057 on selected transcription factors. Unlike ferulic acid, NCX 2057 inhibited LPS-induced translocation/activation of the nuclear factor, NF-kappaB, while other transcription factors, such as, Sp1, NF-IL2A and STAT-1 were not affected. The present data support the concept that NO adds important anti-inflammatory properties to ferulic acid. Thus, NCX 2057 represents a new prototype drug for the treatment of disorders associated with chronic inflammation and oxidative stress.

Authors+Show Affiliations

Nicox Research Institute, Via Ariosto 21, 20091 Bresso, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16443213

Citation

Ronchetti, Daniela, et al. "Modulation of iNOS Expression By a Nitric Oxide-releasing Derivative of the Natural Antioxidant Ferulic Acid in Activated RAW 264.7 Macrophages." European Journal of Pharmacology, vol. 532, no. 1-2, 2006, pp. 162-9.
Ronchetti D, Impagnatiello F, Guzzetta M, et al. Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages. Eur J Pharmacol. 2006;532(1-2):162-9.
Ronchetti, D., Impagnatiello, F., Guzzetta, M., Gasparini, L., Borgatti, M., Gambari, R., & Ongini, E. (2006). Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages. European Journal of Pharmacology, 532(1-2), 162-9.
Ronchetti D, et al. Modulation of iNOS Expression By a Nitric Oxide-releasing Derivative of the Natural Antioxidant Ferulic Acid in Activated RAW 264.7 Macrophages. Eur J Pharmacol. 2006 Feb 17;532(1-2):162-9. PubMed PMID: 16443213.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages. AU - Ronchetti,Daniela, AU - Impagnatiello,Francesco, AU - Guzzetta,Massimiliano, AU - Gasparini,Laura, AU - Borgatti,Monica, AU - Gambari,Roberto, AU - Ongini,Ennio, Y1 - 2006/01/27/ PY - 2005/07/21/received PY - 2005/12/08/revised PY - 2005/12/19/accepted PY - 2006/1/31/pubmed PY - 2006/6/3/medline PY - 2006/1/31/entrez SP - 162 EP - 9 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 532 IS - 1-2 N2 - We have previously reported that NCX 2057, a new chemical entity bearing a nitric oxide (NO)-releasing moiety linked to the natural antioxidant ferulic acid, shows marked anti-inflammatory properties in a model of chronic brain inflammation. We have now studied the effects of NCX 2057 and its metabolic products, ferulic acid and NCX 2059, on inducible nitric oxide synthase (iNOS) expression and function in lipopolysaccharide/interferon-gamma (LPS/IFNgamma)-stimulated RAW 264.7 macrophages. NCX 2057 inhibited iNOS mRNA and protein expression (IC(50)=6.2+/-1.0 microM) without altering iNOS protein degradation rate. NCX 2057 also decreased the levels of LPS/IFNgamma-induced nitrite accumulation (IC(50)=4.3+/-0.7 microM) in RAW 264.7 cells. Conversely, NCX 2059, which does not possess NO-donating properties, was only weakly effective (IC(50) >100 microM) and ferulic acid was inactive. To understand further the mechanisms underlying anti-inflammatory properties we studied the effects of NCX 2057 on selected transcription factors. Unlike ferulic acid, NCX 2057 inhibited LPS-induced translocation/activation of the nuclear factor, NF-kappaB, while other transcription factors, such as, Sp1, NF-IL2A and STAT-1 were not affected. The present data support the concept that NO adds important anti-inflammatory properties to ferulic acid. Thus, NCX 2057 represents a new prototype drug for the treatment of disorders associated with chronic inflammation and oxidative stress. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/16443213/Modulation_of_iNOS_expression_by_a_nitric_oxide_releasing_derivative_of_the_natural_antioxidant_ferulic_acid_in_activated_RAW_264_7_macrophages_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(05)01339-7 DB - PRIME DP - Unbound Medicine ER -